FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending October 20, 2008
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --



Notification of Transactions of Directors, Persons Discharging Managerial 
Responsibility or Connected Persons


I give below details of an increase in interests in Ordinary shares purchased at a price of £11.22 per share, and Ordinary share ADRs purchased at a price of $33.85 per ADR  in  GlaxoSmithKline plc on 15 October 2008, in respect of the personal holdings of the under-mentioned persons following the re-investment of the dividend paid to shareholders on 9 October 2008.

 

Ordinary shares

ADRs

Mr A P Witty

229.89

  

Mr J S Heslop

46.28

  

Dr M M Slaoui

67.34

  

Mrs C E Bruck Slaoui

20.94

  

Mr S M Bicknell

29.93

  

Mr J M Clarke

142.93

  

Mr M Dunoyer

86.58

  

Mr E J Gray

86.89

  

Mr D Learmouth

52.09

  

Mr W C Louv

  

55.88

Mr D J Phelan

  

170.58

Dr D Pulman

  

98.68

Mr D S Redfern

0.39

  

Ms C Thomas

65.37

  

Mr J R Stéphenne

242.27

  


 



The Company was advised of this information on 20 October 2008.


This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).


V A Whyte

Deputy Company Secretary


20 October 2008

 

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: October 20, 2008

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc